Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

5.110 -0.220 (-4.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at Upcoming Sidoti Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter Results on November 7, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Second Quarter Results on August 4, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.